login
  Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

FDA clears first ever bi-directionally retrievable vena cava filter from Crux Biomedical


Thursday, 19 Jul 2012 11:17
Tom Fogarty
Tom Fogarty


The US Food and Drug Administration (FDA) has cleared Crux Biomedical’s inferior vena cava filter with bi-directional retrieval for the prevention of pulmonary embolism. This feature allows retrieval of the device from the femoral or jugular veins, a key consideration when access to one or the other vein is limited.


“Crux designed a device that is both more versatile and simple to use,” said Tom Fogarty, cardiovascular surgeon and founder of Crux Biomedical. “Bi-directional deployment and retrieval are extremely helpful in situations where access to either the femoral or jugular vein is not possible. The Crux vena cava filter with its innovative design and materials represents a paradigm shift in prevention of pulmonary embolisms in patients at risk.”

A recently completed pivotal trial consisting of 125 patients at high risk for pulmonary embolisms, called the RETRIEVEclinical study, was performed at 22 sites in the USA, Australia, New Zealand and Belgium. The study results were presented at the 2012 Society for Interventional Radiology (SIR) meeting.


In the study, the technical success rate of filter deployment was 98%; filter retrieval success was also 98%. The average retrieval time was 7 minutes. By the 6-month follow up of the study, no embolizations, migrations or fractures were observed.


“The Crux device demonstrated excellent deployment, retrieval and safety profile,” stated Robert R Mendes, principal investigator of the study; associate professor of Surgery, University of North Carolina; and Chief of Vascular Surgery, Rex UNC Healthcare. “The clinical study evaluation has demonstrated the Crux vena cava filter can be used safely for the prevention of recurrent pulmonary embolisms.”


“The Crux vena cava filter system is the first major design innovation in vena cava filters in some 40 years,” said Mel Schatz, CEO, Crux Biomedical. “We have been pleased with both the clinical outcomes in our pivotal clinical trial and the enthusiasm expressed by physicians using the Crux vena cava filter.” The device’s novel helical shape was designed to self-center and to conform more closely to the shape of the vena cava, as well as to reduce bends and stress that can compromise filter integrity.




Add New Comment

Related Items


Most popular


New varicose vein treatment available in Europe
Monday, 16 Feb 2015
VariClose is a new technique by which an incompetent saphenous vein is sealed through embolisation. New varicose vein treatment available in Europe

IN.PACT Admiral drug-eluting balloon receives FDA approval
Monday, 05 Jan 2015
In the IN.PACT SFA trial, the device demonstrated the lowest clinically-driven target lesion revascularisation rate (2.4%) ever reported for an interventional treatment of peripheral arterial disease ... IN.PACT Admiral drug-eluting balloon receives FDA approval

Medtronic completes acquisition of Covidien
Tuesday, 27 Jan 2015
Under the terms of the acquisition agreement, Medtronic Inc and Covidien plc are now combined under Medtronic plc. Medtronic completes acquisition of Covidien

Features


“We are helping surgeons operate on sicker patients”
Wednesday, 25 Feb 2015
Daniel B Brown, Vanderbilt-Ingram Cancer Center, Nashville, USA, puts together a 2015 checklist on the latest portal vein embolization developments for Interventional News readers. “We are helping surgeons operate on sicker patients”

SIR 2015: Take home new skills and perspectives from Atlanta
Thursday, 15 Jan 2015
Jafar Golzarian, SIR 2015’s programme chair, discusses some of the most exciting sessions from the Society of Interventional Radiology’s (SIR’s) upcoming Annual Scientific Meeting (28 February–5 M... SIR 2015: Take home new skills and perspectives from Atlanta

Profiles


Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

José Ignacio Bilbao Jaureguízar
Wednesday, 08 Oct 2014
“No matter what their future orientation, interventional radiologists involved in interventional ... José Ignacio Bilbao Jaureguízar

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions